Temporal variations in ischemic and bleeding event risks after acute coronary syndrome during dual antiplatelet

Toshiharu Fujii1, Satoshi Kasai2, Yota Kawamura2

  • 1Division of Cardiology, Tokai University School of Medicine, Isehara, Japan; Division of Cardiology, Tokai University Hachioji Hospital, Hachioji, Japan.

PubMed

Insights

A 60-day dual antiplatelet therapy (DAPT) duration balances ischemic and bleeding risks after acute coronary syndrome (ACS). This duration is effective regardless of a patient's high bleeding risk (HBR) status.

Area of Science:

  • Cardiology
  • Clinical Research
  • Pharmacology

Background:

  • Dual antiplatelet therapy (DAPT) is crucial after acute coronary syndrome (ACS).
  • Patient stratification using Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria is essential.
  • Understanding temporal risk variations in ischemic and bleeding events during DAPT is critical.

Purpose of the Study:

  • To estimate temporal risk variations of ischemic and bleeding events during DAPT.
  • To stratify patients based on ARC-HBR criteria.
  • To determine the optimal DAPT duration after ACS.

Main Methods:

  • 1264 ACS patients receiving aspirin plus clopidogrel or prasugrel were classified by ARC-HBR.
  • Multicenter observational study design.
  • Cox hazard and Royston-Parmar models used to estimate temporal risk variations.

Main Results:

  • Ischemic events occurred in 9.4% and bleeding events in 7.4% over 313 days.
  • High bleeding risk (HBR) patients had significantly higher rates of both ischemic (15.3%) and bleeding (11.9%) events.
  • Ischemic event risk surpassed bleeding event risk within 60 days for both HBR and non-HBR groups.

Conclusions:

  • A 60-day DAPT duration effectively balances ischemic and bleeding event risks post-ACS.
  • This DAPT duration is appropriate irrespective of the patient's ARC-HBR classification.
  • The findings support a standardized 60-day DAPT regimen for ACS patients.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
559
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
20
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.6K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
9
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11